Contemporary oncology drug development increasingly requires efficient dose-optimization strategies that evaluate monotherapy (Mono) and combination therapy (Combo) while balancing activity, efficacy, and tolerability. We propose a staggered seamless phase I/II design for settings in which a novel agent is evaluated al...
Randomized controlled trials remain the benchmark for estimating treatment effects, yet practical constraints often restrict sample sizes in a prespecified target population. In such settings, evidence from completed trials is frequently available only in aggregate form, which precludes direct individual-level integrat...
Keisuke Hanada, M. Kojima· Biometrical journal. Biometr...· 1 citation
This work treats the entire backward-fitting rule as the unit of comparison and proposes feedback-aware soft tuning for sequential multiple assignment randomised trials and an exact risk identity under a Gaussian shift model and an oracle inequality with an explicit adaptation remainder under coordinate-representation...
Design-stage power and sample-size evaluation under biased-coin minimization can be computationally intensive when a prespecified randomization test is reproduced within every simulated trial. We develop a reusable stratum-imbalance Gaussian approximation (SIGA) framework by exactly decomposing a fixed-score statistic...
M. Kojima· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.